Wyeth launches major Phase IV trial of new pneumonia vaccine in the elderly
This article was originally published in Scrip
WyethPharmaceuticals has announced the start of its Community Acquired Pneumonia Immunization Trial in Adults (CAPITA), a major Phase IV study investigating its investigational 13-valent conjugate vaccine, Prevenar-13, designed for the prevention of pneumococcal pneumonia – the leading cause of bacterial pneumonia in adults.
You may also be interested in...
Somaxon Pharmaceuticals and Procter & Gamble Pharmaceuticals are to co-promote Somaxon's insomnia drug Silenor (low-dose doxepin) in the US.
GlaxoSmithKline has begun the Phase III clinical trials programme for its adjuvanted vaccine candidate (GSK1437173A) against herpes zoster for the prevention of shingles.
The EMA has accepted Optimer Pharmaceuticals' MAA for its narrow-spectrum antibiotic fidaxomicin for the treatment of Clostridium difficile infection (CDI) and for the prevention of recurrences of CDI.